A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy.

Trial Profile

A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms COMMAND-2; HEPCAT
  • Most Recent Events

    • 22 Apr 2012 12-Week results presented at the 47th Annual Meeting of the European Association for the Study of the Liver.
    • 04 Apr 2012 Results will be presented at EASL-2012 according to a Bristol-Myers Squibb media release.
    • 17 Jan 2012 Planned End Date changed from 1 Dec 2012 to 24 Feb 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top